Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7 by Gee, Antony David et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1186/s13550-017-0275-2
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Gee, A. D., Enrico Fantoni, & Lovestone, S. (2017). Design, synthesis and evaluation in an LPS rodent model of
neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7. EJNMMI research. DOI: 10.1186/s13550-
017-0275-2
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
ORIGINAL RESEARCH Open Access
Design, synthesis and evaluation in an LPS
rodent model of neuroinflammation of a
novel 18F-labelled PET tracer targeting P2X7
Enrico Raffaele Fantoni1, Diego Dal Ben2, Simonetta Falzoni3, Francesco Di Virgilio3, Simon Lovestone4
and Antony Gee1*
Abstract
Background: The P2X7 receptor has been shown to play a fundamental role in the initiation and sustenance of
the inflammatory cascade. The development of a novel fluorine-18 PET tracer superior and with a longer half-life
to those currently available is a promising step towards harnessing the therapeutic and diagnostic potential
offered by this target. Inspired by the known antagonist A-804598, the present study outlines the design via
molecular docking, synthesis and biological evaluation of the novel P2X7 tracer [18F]EFB. The tracer was
radiolabelled via a three-step procedure, in vitro binding assessed in P2X7-transfected HEK293 and in B16 cells by
calcium influx assays and an initial preclinical evaluation was performed in a lipopolysaccharide (LPS)-injected rat
model of neuroinflammation.
Results: The novel tracer [18F]EFB was synthesised in 210 min in 3–5% decay-corrected radiochemical yield (DC RCY),
>99% radiochemical purity (RCP) and >300 GBq/μmol and fully characterised. Functional assays showed that the
compound binds with nM Ki to human, rat and mouse P2X7 receptors. In vivo, [
18F]EFB displayed a desirable distribution
profile, and while it showed low blood–brain barrier penetration, brain uptake was quantifiable and displayed significantly
higher mean longitudinal uptake in inflamed versus control rat CNS regions.
Conclusions: [18F]EFB demonstrates strong in vitro affinity to human and rodent P2X7 and limited yet quantifiable BBB
penetration. Considering the initial promising in vivo data in an LPS rat model with elevated P2X7 expression, this work
constitutes an important step in the development of a radiotracer useful for the diagnosis and monitoring of clinical
disorders with associated neuroinflammatory processes.
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Background
The P2X7 receptor has been identified as a key player in
the neuroinflammatory cascade leading to the onset and
progression of a wide range of CNS conditions [1]. For
example, in Alzheimer’s disease, it is crucial in mediating
the secretion of interleukin-1β following beta-amyloid
stimulation [2]. Likewise, neuropathic pain is directly re-
lated to P2X7’s action on IL-1β maturation [3] and ca-
thepsin release [4]. Therefore, the development of a
non-invasive selective PET ligand targeting P2X7 would
enable further understanding of the role of this import-
ant receptor, as well as providing a measurable outcome
for clinical trials and providing a new avenue for the
diagnosis of neuroinflammation.
Over the last decade, a number of PET tracers have
been developed and evaluated (Fig. 1). Neither [11C]A-
740003 nor [11C]SMW64-D16 showed appreciable brain
uptake; however, both succeeded in recognising the site of
inflammation in two different rodent models when exam-
ined by in vitro autoradiography [5, 6]. [11C]GSK1482160,
however, shows greater promise due to its efficient radio-
synthesis and strong P2X7 selectivity and blood–brain
barrier (BBB) permeability, but its preclinical evaluation is
still in progress [7].
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This study presents the novel fluorine-18-labelled PET
tracer [18F]EFB 2-cyano-1-(4-[18F]fluorobenzyl)-3-(quino-
lin-5-yl)guanidine developed from the known blood–brain
barrier permeable P2X7 antagonist A-804598 [8, 9]. Cya-
noguanidines have been investigated at length due to their
strong pharmacological activity and affinity for P2X7
across a number of analogues. This includes the discovery
that an N-quinoline substituent results in higher binding
affinity compounds compared with analogues with smaller
or less hydrophilic aromatic rings [10, 11], and that a 1-
carbon guanidine-phenyl linker is more desirable than
longer and more functionalised analogues [12–14]. In-
stead, the cyanoguanidine core is thought to provide rigid-
ity to the molecular structure by hydrogen bonding with
the receptor-binding pocket [15]. Hence, compound EFB
is ideally placed to display an optimal fit into the binding
pocket while featuring a fluorine-18 label. The work pre-
sented here includes a molecular docking analysis of the
structure–affinity relationship (SAR) between the receptor
ATP-binding pocket and both the benzyl-desmethylated
derivative of A-804598 and compound EFB. The synthesis
and radiolabelling of all compounds required for the syn-
thesis of [18F]EFB are also described. Finally, the biological
evaluation of [18F]EFB in P2X7-transfected cells and in an
intraperitoneal lipopolysaccharide (LPS) preclinical model
of inflammation is presented.
Methods
Molecular modelling
All molecular modelling studies were performed on a
Core i7 CPU (PIV 2.20 GHZ) PC workstation. Hom-
ology modelling studies of the human P2X7 (hP2X7)
were carried out using the closed state zebrafish
P2X4 (zP2X4) receptor as a template, as described in
Dal Ben [15]. Molecular Operating Environment
(MOE by C.C.G., Montreal, CA, version 2012.10)
suite was employed for this task. The ligand struc-
tures were docked into the binding site of the P2X7
receptor using the AutoDock tool (PyrX interface) by
the Scripps Institute [16, 17]. All docking conformations
were then imported in MOE, and the partial charges were
assigned by semi-empirical RHF/AM1 calculations using
the MOPAC package [18] implemented in MOE. Further
details are provided in Additional file 1.
Chemistry
Hereafter, the synthesis of precursor 6 and of the reference
compound EFB is briefly described (Fig. 2). Full com-
pound characterisation is described in Additional file 1,
together with the synthesis of compounds 4 and 2.
For the synthesis of methyl N′-cyano-N-5-quinolinylcar-
bamimidothioate (6), a mixture of 5-isothiocyanatoquinoline
(2, 6.38 g, 34.3 mmol) and sodium hydrogencyanamide
(2.19 g, 34.3 mmol) in dimethylformamide (30 mL) was
stirred at room temperature for 1 h. Methyl iodide
(2.13 mL, 34.3 mmol) was added at 0 °C, and the reaction
was stirred at room temperature for 2 h. The reaction was
poured into water and stirred further for 20 min. The or-
ange precipitate was filtered and washed with water. Further
purification was performed by flash chromatography on
SiO2 (EtOAc:CH2Cl2, 1:1) to obtain methyl N′-cyano-N-
(quinolin-5-yl)carbamimidothioate (compound 6) as an or-
ange solid in 70.0% yield (5.77 g).
In line with previously published procedures [8], for
the synthesis of 2-cyano-1-(4-fluorobenzyl)-3-(quino-
lin-5-yl)guanidine (EFB), a mixture of 0.62 mL 4-
fluorobenzyl amine 3 (5.36 mmol, Alfa Aesar) and
1.12 mL triethylamine (8.04 mmol) was added to com-
pound 2 (1 g, 5.36 mmol) in 25 mL anhydrous tetra-
hydrofuran (THF) and stirred for 1 h at room
temperature. Following the addition of mercury acetate
(5.36 mmol) and sodium hydrogen cyanamide
(16.1 mmol), the mixture was stirred for 24 h until dark
black. The mixture was filtered under reduced pressure
through a short pad of celite and washed with acetone
(30 mL). The filtrate was concentrated by rotary evap-
oration and purified by flash chromatography (SiO2, 8–
10% MeOH in Et2O, then 0–25% EtOAc in 10% MeOH
in Et2O). The product was then dried by rotary evapor-
ation and recrystallized from acetone as a white powder
in 8% yield (140 mg).
Radiochemistry
Chromatography
Chemical and radiochemical purities were assessed by
analytical radio- and UV-HPLC as outlined in Table 1.
The chemical identity of [18F]EFB was confirmed by com-
parison with its respective standard reference compound,
while intermediate radioactive species were confirmed by
thin-layer chromatography (TLC). The molar radioactivity
Fig. 1 Chemical structures of A-804598 and of the P2X7 PET tracers described to date in the literature, including our novel P2X7 ligand [18F]EFB
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was determined via a standard UV curve with a sample of
the product in its final formulation. All radiochemical
yields (RCY) are reported as decay-corrected values.
Radiosynthesis
[18F]Fluoride was produced using an RDS112 cyclotron
at King’s College London PET Centre by the 18O(p,n)18F
reaction via proton irradiation of enriched (95%) 18O
water. 1–1.5 GBq of aqueous [18F]fluoride were trapped
in a Sep-Pak Accell Plus QMA cartridge (WAT023525)
pre-activated with 5 mL 1 N NaOH, 10 mL water and
5 mL 1 N K2CO3 followed by 10 mL water. The fluoride
was released with 0.65 mL 30 mM:15 mM Kryptofix
222/potassium carbonate dissolved in 85:15 acetonitrile/
water. The solution was dried three times at 90 °C for
5 min in a Wheaton V vial and under a flow of nitrogen.
For the synthesis of 4-fluorobenzonitrile ([18F]5), the
method reported by Koslowsky [19] was followed with
some modifications. To dried [18F]fluoride (1–1.5 GBq),
4-cyano-N,N,N-trimethylanilinium trifluoromethansulfo-
nate 1 (2 mg) in DMSO (0.3 mL) was added and reacted
for 15 min at 110 °C. Once the reaction was completed,
the mixture was diluted with water (30 mL) and passed
through a Waters Sep-Pak tC18 Plus Long SPE cartridge
(WAT036800). The cartridge was washed with add-
itional water (5 mL) before elution of compound [18F]5
in 2 mL THF in 40–60% RCY and >95% radiochemical
purity (RCP). Radio-TLC (SiO2, petroleum ether/ethyl
acetate (1:1), Rf 0.7; lit. [19] 0.7).
For the synthesis of 4-fluorobenzyl amine ([18F]3), 2 mL
[18F]5 in THF was transferred without further purification
into a reaction vial containing 10 mg NaBH4 and 5 mg
Co(OAc)2. To this, 1 mL water was added and the mixture
was mixed and allowed to react at RT for 3 min. Next, the
mixture was diluted in 40 mL pH 6.2 phosphate buffer
(6.7:1 1 M NaH2PO4:1 M Na2HPO4, I = 9 mM) so as to
limit the organic solvent to 5%. The mixture was filtered
(0.2-μm pore Whatman Spartan filters) and loaded on a
Phenomenex Strata-X-CW SPE cartridge (8B-S035-FBJ).
Following a 5 mL acetonitrile wash, a purple band charac-
teristic of compound [18F]3 formed in the cartridge and
could be entirely eluted in the second of three aliquots of
0.6–0.7 mL 5% TFA acetonitrile in 45–55% RCY (22–34%
overall RCY) and >93% RCP. Radio-TLC (SiO2, nBuOH/
HOAc–H2O (4:1:1), Rf = 0.4; lit.[19] 0.4).
Finally, for the synthesis of [18F]EFB, 0.4–0.7 mL of [18F]3
in 5% TFA acetonitrile were neutralised with 2 eq. triethyla-
mine (110–112 μL) and added to 11 μmol of compound 6
(3.6 mg) in a sealed vessel. The reaction vessel was heated
at 160 °C for 15 min, cooled to 50 °C and the solvent was
concentrated at 50 °C under a stream of nitrogen for 7–
10 min. Next, the crude mixture was diluted in 2 mL water
ensuring <15% acetonitrile was present and injected in an
HPLC semi-prep C18 column to provide isolation of the
pure product in >99% RCP and >300 GBq/μmol molar
radioactivity. The product was diluted to 30–50 mL in
water and passed through a light C18 Short Sep-Pak SPE
cartridge (WAT023501) for concentration in 200–500 μL
ethanol. The resulting product was obtained in high purity
Table 1 HPLC methods
Method EFB Rt
(min)
Flow rate
(mL/min)
Column Mobile phase gradient Mobile phase UV (nm)
A 51’10” 3 Agilent eclipse XDB C18,
9.4 × 250 mm, 5 μm, 100 Å
15% B for 5 min; 15–35% B for 1 h; 35% B for
2 min; 35–20% B for 2 min; 20% B for 1 min
A: H2O 254
B: MeCN
B 19’10” 1 Kinetex Phenomenex XB-C18 with
guard, 4.6 × 150 mm, 5 μm, 100 Å
30 s at 20% B; 23.5 min 20–33.5% B; 3 min
33.5–70% B; 2 min 70% B; 1 min 70–20% B
A: H2O 300
B: MeCN
Fig. 2 Radiosynthetic route to [18F]EFB. a [18F]KF.K222, 15 min, 110 °C in DMSO followed by tC18 Sep-Pak SPE. b 2:1 w/w NaBH4/Co(OAc)2 in 2 mL:1 mL
THF/H2O, 5 min followed by Strata-X-CW purification in acidic media. c Excess triethylamine, THF, 140 °C, HPLC purification and concentration on a light
C18 Sep-Pak SPE cartridge
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and 4.0% overall RCY in 3 h and 30 min from start of syn-
thesis. Purity tests were performed with HPLC method B
(Table 1). A stability test performed in 0.05% DMSO at
37 °C for 2 h indicated no radioactive by-product forma-
tion and high retention of its UV-active fingerprint
(254 nm, Additional file 1: Figure S1).
Optimisation of the reaction conditions
Iterative optimisation steps were performed with the use
of 100–150 MBq starting [18F]fluoride and were aimed at
improving the radiochemical yield of each step of the
radiosynthesis. The influence of the following parameters
was explored by TLC (compounds [18F]5 and [18F]3) and
HPLC analysis ([18F]EFB) of 50 μL reaction mixture sam-
ples filtered and diluted to 200 μL in water:
 Temperature
 Precursor concentration
 Time
 Purification technique
 Catalytic base concentration
In vitro affinity assays
The materials and methods employed in this section
are described in full in Cabrini 2005 [20] and in Add-
itional file 1. Briefly, HEK293 were transfected with
the calcium phosphate method described in Rizzuto
[21] and Morelli [22]. Stably P2X7-transfected, single-
cell-derived clones were obtained by limiting dilu-
tions. Transfected cells were then kept under selec-
tion in the presence of 0.2 mg/ml G418 sulfate.
Instead, B16 cells natively expressed the mouse P2X7
receptor. Experiments were performed in a Ca2+-con-
taining (1 mM) saline solution (150 mM NaCl, 5 mM
KCl, 1 mM MgCl, 5.5 mM glucose, 20 mM Hepes,
pH 7.4) at 37 °C with a PerkinElmer fluorimeter.
Cells were loaded with 1 μM of the fluorescent indi-
cator Fura-2/AM for 30 min in the presence of
250 μM sulfinpyrazone to reduce excretion of intra-
cellular Fura-2. Cells were then rinsed and resus-
pended in saline solution at a final concentration of
500,000/ml [23]. Excitation ratio and emission wave-
lengths were 340/380 and 505 nm, respectively. The
calcium ionophore ionomycin (1 μM) was added at
the end of each time course as an internal assay con-
trol. Inhibitory activity was measured as intracellular
Ca2+ ([Ca2+]i) flux variation from baseline while in
the presence of 100% activating BzATP (100 μM for
hP2X7 and rP2X7, 200 μM for mP2X7). Inhibition
was measured on both peak and plateau phases. The
final value was chosen as the most accurate of the
two measurements, or alternatively from the plateau.
A-740003 was purchased from TOCRIS Bioscience.
Preclinical
Animals
Male Sprague–Dawley rats of 240–270 g were bought
from Charles River Laboratories International, Inc., and
used within 90 days. The animals were housed with a
week of acclimatisation before procedures were done
under pathogen-free conditions in a temperature- and
humidity-controlled environment and given access to
food and water ad libitum. All experiments were carried
out in the Rayne Institute, St. Thomas’ Hospital, King’s
College London, between 2015 and 2016 and according
to the Animals Act 1986 and with the approval of the
King’s College research ethics committee.
Injections
Twenty-four hours prior to scanning, all rats were pre-
treated by an intraperitoneal injection of 0.5 mg/kg LPS
from Escherichia coli (0111:B4 L2630, Sigma Aldrich) at
0.5 mg/mL or with 1 mL/kg sterile saline solution and
weighed before the start of the PET imaging procedure.
Then, the saline-dissolved reformulated radiotracer was
injected under isoflurane anaesthesia in 0.2–5 MBq, cor-
responding to an administered dose of 0.5–16 ng/kg,
and >300 GBq/μmol molar radioactivity via tail vein can-
nulation, followed by a 0.15 mL saline flush. Details on
anaesthesia and PET/CT acquisition and analysis are re-
ported in Additional file 1. Immediately after imaging,
the animals were culled by terminal anaesthesia and cer-
vical dislocation and dissected. Organs and body fluids
were collected for gamma counting (LKB Wallac 1282)
and biodistribution analysis.
Statistical analysis
Data are expressed as mean ± standard error mean
(SEM) from three independent replicates, unless other-
wise indicated. Statistical analysis of the %ID/g variation
in the PET scans and biodistributions were performed
with GraphPad Prism 5.0 (San Diego, USA) as a para-
metric two-way ANOVA test with Bonferroni post-test,
while the mean longitudinal percentage injected dose
per gram (%ID/g) and the post-LPS treatment weight
variation were analysed with a Student’s t test. The aster-
isk indicates P < 0.01; **P < 0.005; ***P < 0.001. Where
unspecified, no significance was found.
Results
Molecular docking
Compound EFB as well as A-804598 and its benzyl-
desmethylated derivative were docked at the hP2X7
binding site, and the docking conformations of the three
compounds are shown in Fig. 3.
The removal of the benzyl methyl group of A-804598
only marginally affected the strength of ligand–receptor
docking scores due to the decreased interaction with the
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hydrophobic pocket between Y288 and F218 (Table 2).
Nevertheless, it did not alter the three-dimensional con-
formation of the substrate if not by reducing the struc-
tural constraint on the external phenyl group to sit
between F218 and K66, leading to minor losses in dock-
ing scores. These were not substantially modified either
by the insertion of a para-fluorine atom useful as a ra-
diolabel, which appeared to comfortably sit at the outer
opening of the pocket.
Chemistry
The synthesis and characterisation of precursors 4 and 6
as well as of the reference compound EFB (Fig. 4) were
successfully carried out. The synthesis of 6 and EFB in-
volved two steps starting from 5-aminoquinoline and was
achieved in 43.4 and 5.6% overall yields, respectively.
Radiochemistry
The radiofluorination procedure loosely followed methods
previously reported by Koslowsky [19] and Turkman [24].
The protocol, described in the materials and methods,
was modified to increase the radiosynthetic reliability by
iterative reaction parameter modifications and alterations
to the purification strategies.
Optimisation of the reaction conditions
Firstly, in order to minimise the cold carrier reactants in
the reaction pot as a means to achieve high molar radio-
activities, the procedure for the synthesis of [18F]5 was
modified to suit 1–2 mg of precursor (3.2–6.4 μmol). Se-
quential modification of the time and temperature of re-
action enabled to conclude that 6.4 μmol precursor
reacted with [18F]fluoride at 110 °C for 15 min afford a
maximal RCY of 75.9 ± 4.7%, superior to that described
elsewhere [19] (Table 3).
The nitrile reduction of [18F]5 to [18F]3 was monitored
by TLC ([18F]3 Rf 0.7) at three time points while main-
taining the reagent proportions indicated in Koslowsky
[19]. As indicated in Table 4, maximal RCYs were ob-
tained with 3 min of exposure of the reagents to a re-
ductive environment.
In our hands, the isolation of [18F]3 by Waters C18 plus
Sep-Pak solid phase extraction in basic media [19] gave
poorly consistent product recoveries of <50%. Instead,
much higher reliability and up to 60% recoveries were
achieved with a Phenomenex Strata-X-CW weak cation
exchange cartridge as described in Additional file 1.
For the synthesis of [18F]EFB, iterative variation of the
reaction conditions was performed while maintaining
11 μmol of reagent 6 in a 1 mL solution of compound
[18F]3 in MeCN + 5% TFA in the presence of 2 eq. of
triethylamine with respect to TFA. Despite the lack of a
statistically significant variation in yield, maximal
product formation and near-total reactant consump-
tion was achieved at 160 °C in 15 min, as outlined in
Table 5 and Fig. 5.
Table 2 Post-docking affinity analysis
Compound Binding_energy (kcal/mol) Dock_pKi
A-804598 −6.31 5.14
Desmethyl-A-804598 −5.92 4.87
EFB −5.72 4.90
Fig. 3 Molecular docking of compounds A-804598 (left), its benzyl-desmethylated derivative (middle) and EFB (right) into the hP2X7 receptor
ATP-binding pocket
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Purification and quality control of [18F]EFB
The product was purified by semi-preparative chro-
matography using method A (Table 1, Fig. 6a) and
identified by co-elution with an authentic reference
compound with method B (Table 1, Fig. 6c). Quality
control was performed after purification and reformu-
lation, typically yielding an HPLC chromatogram
similar to that shown in Fig. 6b and pH within a
physiological range. The desired product [18F]EFB had
a retention time of 19.35 min.
In vitro affinity
The affinity of EFB for P2X7 was determined by cal-
cium influx assays in transfected HEK293 and B16
cells and compared with A-740003 affinities (Table 6).
For EFB, the assays showed 5.74 pIC50 for the human
receptor isoform, 5.14 pIC50 for rat and 5.22 IC50 for
mouse P2X7. Assuming competitive inhibition as per
A-804598 [8], the values were transformed to their
respective inhibition constants (Ki) by means of the
Cheng–Prusoff equation [25]. Here, pEC50 values for
100% P2X7-activating BzATP (6.8 ± 0.14 in human,
6.3 ± 0.13 in rat and 4.7 ± 0.07 in mouse) were calcu-
lated with respect to the YoPro dye uptake response
in P2X7-HEK293 cells as reported in Hibell [26]. This
resulted in 2.88 nM Ki in human P2X7, 36.1 nM in
rat and 547 nM in mouse. Similar calculations were
performed for the known antagonist A-740003, for
which literature values useful as internal reference are
provided.
Preliminary in vivo evaluation
LPS model validation
LPS injections are known to induce a 5–10% weight loss
within 24 h, which is known to indicate activation of the
inflammatory process [27, 28]. In this work, the valid-
ation of the LPS rat model was restricted to recording a
significant weight loss for all treated rats after 24 h
(Additional file 1: Figure S3).
[18F]EFB evaluation
Evaluation of [18F]EFB as an inflammation-dependent
tracer was performed by comparison of control and
0.5 mg/kg LPS-pre-treated Sprague–Dawley rats. The
visual PET image assessment indicates low brain up-
take with slightly increased retention in the LPS rat’s
temporal lobe (Fig. 7, also displaying elevated retinal
uptake). Rat longitudinal uptake profiles (Fig. 8) re-
vealed a relatively stable blood concentration around
0.05–0.1%ID/g. The CNS uptake stayed between
0.05–0.1%ID/g for the spinal cord, while it reached
0.02–0.07%ID/g in the whole brain, the cortex, the ol-
factory bulb, the cerebellum and the basal ganglia.
These percentages closely correlate with the terminal
biodistribution (Fig. 9). Additionally, LPS-treated rats
demonstrated a statistically significant increase in
mean tracer uptake compared to untreated rats, pos-
sibly reflective of increased P2X7 expression.
Discussion
The development of the novel radioligand [18F]EFB rep-
resents a valuable advancement to the field of P2X7 PET
imaging. Molecular docking analysis of the benzyl-
desmethylated version of A-804598 and of EFB indicated
that subtle structural modifications in the periphery of
the A-804598 scaffold are not predicted to impact the
affinity to the target’s ATP-binding pocket [8], thus
Table 3 Iterative n.i. RCY optimisation of compound [18F]5. Values
derived from TLC chromatogram analysis
Entry Scale (μmol
precursor)
Time (min) Temperature (°C) RCY (% ± SEM)
1 3.2 15 95 63.0 ± 4.1 (n = 8)
2 3.2 20–25 95 65.2 ± 7.4 (n = 3)
3 3.2 15 110 42.9 ± 3.7 (n = 2)
4 6.4 15 95 68.0 ± 17 (n = 2)
5 6.4 15 110 75.9 ± 4.7 (n = 4)
6 6.4 20 110 66.9 ± 3.2 (n = 2)
Table 4 N.i. RCY TLC monitoring at different time points for the
synthesis of [18F]3
Entry Time (min) Temperature (°C) RCY (% ± SEM)
1 1 25 67.1 ± 3.0 (n = 3)
2 3 25 90.1 ± 4.1 (n = 7)
3 5 25 82.5 ± 5.5 (n = 14)
Fig. 4 Synthetic route to EFB
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offering the possibility of attaching a fluorine-18 label to
the externally oriented phenolic ring of A-804598.
The synthesis of EFB was achieved via mercury sulfide
precipitation-driven stepwise amine addition in moder-
ate yields, possibly due to interaction of the transition
metal with the guanidine moiety. Radiolabelling was
achieved in three steps starting from compound 4,
achieving an overall DC RCY of 3–5%, >99% RCP and
>300 GBq/μmol molar activity. The RCY was mostly
limited by the inherently high unknown by-product for-
mation in the final step of the process. This could con-
sist in a cyclised or truncated form of [18F]EFB, which
could be limited by the replacement of precursor 6 with
an analogue with a more labile leaving group, such as
sulfonyl methane [29] or sulfonyl chloride [30]. However,
some preliminary attempts at oxidising the thiomethyl
group with 2 eq. oxone at room temperature or m-
CPBA at −20 °C resulted in over-oxidation of compound
6. The RCY was found to be sensitive to variations due
to limited SPE recoveries unless large crude product di-
lutions were carried out.
In vitro affinities were derived from calcium influx
binding assays in the presence of the calcium-sensitive
dye Fura-2/AM in stably P2X7-transfected cells. The
typical ATP-mediated Ca2+ flow response is a sharp peak
followed by a sustained plateau phase [31]. Given the
high P2X7 expression, despite the values reported repre-
sent the former, the inhibition constants were in a simi-
lar range for both the peak and plateau phases. The
variation in affinity between the receptor isoforms
Fig. 6 a Semi-preparative purification of the product [18F]EFB with HPLC
method A (Table 1). b Final [18F]EFB analytical chromatogram (RCP >99%,
high CP) with HPLC method B. c Identification of [18F]EFB by co-elution
with the reference standard with HPLC method B. Green chromatograms,
UV; blue/red chromatograms, radioactivity. Only the region marked by the
dashed red lines around 51 min was subject to collection
Table 6 EFB and A-740003 calcium influx inhibition of P2X7
receptor subtypes
P2X7
isoform
Cell line [BzATP]
(μM)
pIC50 Lit. pIC50 Ki (nM) pKi
Human P2X7-HEK293 100 5.74 n/a 2.88 8.54
Rat P2X7-HEK293 100 5.14 n/a 36.1 7.44
Mouse P2X7-B16 200 5.22 n/a 547 6.26
Human P2X7-HEK293 100 7.18 7.36 [32] 0.10 9.98
Rat P2X7-HEK293 100 5.76 7.75 [32] 8.67 8.06
Mouse P2X7-B16 200 5.97 6.57 [34] 97.20 7.01
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Fig. 5 [18F]EFB n.i. RCY changes with temperature. Black, [18F]EFB; blue,
unknown by-product; red, unreacted [18F]3
Table 5 HPLC monitoring of the n.i RCY of [18F]EFB
Entry Temp
(°C)
[18F]EFB RCY
(% ± SEM)
Unreacted
compound 3
RCY (% ± SEM)
Major by-product
RCY (% ± SEM)
1 120 41.4 ± 8.2 (n = 2) 7.0 ± 0.8 (n = 2) 13.7 ± 4.5 (n = 2)
2 125 39.0 ± 7.9 (n = 2) 15.3 ± 10.6 (n = 2) 19.6 ± 14.9 (n = 2)
3 130 43.5 ± 8.9 (n = 2) 10.1 ± 2.2 (n = 2) 41.4 ± 8.2 (n = 2)
4 140 35.9 ± 2.4 (n = 2) 6.2 ± 2.2 (n = 2) 47.6 ± 3.3 (n = 2)
5 150 41.1 ± 2.3 (n = 3) 4.5 ± 1.9 (n = 3) 38.5 ± 2.5 (n = 3)
6 160 43.8 ± 0.8 (n = 2) 3.5 ± 1.8 (n = 2) 38.6 ± 2.9 (n = 2)
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reflects the trends observed for analogous ligands
[32, 33] and indicated a stronger interaction with the
human form. This could lead to the underestimation
of the sensitivity of this ligand upon clinical translation.
The EFB affinity values arising from this assay were found
in parallel to those of the known antagonist A-740003,
which were compared to literature values arising from simi-
lar assay formats [32, 34]. In our in vitro assays, A-740003
appeared less tightly P2X7 binding than apparent from the
literature, suggesting that also EFB IC50s may result
Fig. 7 Selected coronal and sagittal tile views of PET/CT scans at 22.5 min in control (ctrl) and LPS male Sprague–Dawley rats injected with comparable
doses of [18F]EFB. Tile numbers nominally indicate the distance of the slice from the front (coronal) and left side (sagittal) of the brain, but do not
necessarily correspond between different animals. The grey scale in Hounsfield units (HU) refers to the CT data, while the colour scales in Bq/mL refer to
the control rat (left) and LPS rat (right) PET data
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somewhat stronger in different experimental conditions
[26]. Moreover, it remains important to clarify if its selectiv-
ity to P2X7 differs from its cyanoguanidine analogue A-
804598 [8] and to further elucidate whether EFB is truly a
competitive inhibitor, as suggested by Donnelly-Roberts [8]
and Honore [14] for analogous structures, but recently
questioned by Karasawa [35]. A binding modality other
than competitive would preclude the use of the Cheng–
Prusoff equation in its basic form [36].
A preliminary preclinical evaluation of [18F]EFB was
carried out with the intention of clarifying its in vivo
biodistribution and P2X7 binding and to explore its abil-
ity to penetrate the BBB. The use of the bacterial endo-
toxin lipopolysaccharide (LPS)-inflamed rat model was
decided to enable comparison between the tracer uptake
under low and high P2X7 expression levels. This is
known to induce increased P2X7 expression as demon-
strated by immunohistochemical staining of rat brains
24 h after an intraperitoneal 0.5 mg/kg LPS injection
[28]. Additionally, LPS-injected rats display protracted
microglial activation [37, 38] and raised levels of a range
of blood inflammatory markers, including TNF-α, NF-κβ
Brain
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Fig. 8 In vivo %ID/g of [18F]EFB in 24 h post-LPS injection and control rats (n = 3). Matched time and treatment variation significances representative
of overall variations in the uptake are reported for each organ. Statistical analysis was carried out by a parametric two-way repeated measures ANOVA
with column matching and with Bonferroni post-test. The asterisk indicates P < 0.01; **P < 0.005; ***P < 0.001
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and IL-1β [39]. Moreover, brain cortex expression of IL-
1β, IL-6, toll-like receptors (TLRs) and glial fibrillary
acidic protein (GFAP) are upregulated within 4 h, sug-
gesting that glial activation and neuronal inflammation
quickly follow systemic inflammatory episodes [40, 41],
often outlasting them [42]. These biochemical changes
are concomitant with an exaggerated weight loss [43, 44],
and this measure was employed in this work to demon-
strate effectiveness of the LPS treatment. A full validation
of the process linking LPS to P2X7 upregulation is on-
going. The 0.5 mg/kg LPS dose was preferred to higher
doses based on reports that below 3 mg/kg, the endotoxin
does not cause BBB disruption [45].
[18F]EFB displays a desirable in vivo distribution and
excretion profile in that target tissue retention is quanti-
fiable and that fast removal of the radioactivity predom-
inantly via the urinary route can be observed. The brain
uptake of the tracer is quantifiable but low, suggesting
that [18F]EFB could be a substrate of BBB efflux pumps
or that its lipophilicity may benefit from a reduction by
scaffold modifications (EFB: LogP 2.72 by miLogP [46]).
However, the higher affinity of EFB for the human P2X7
isoform may result in enhanced CNS uptake and reten-
tion in a clinical setting.
The mean longitudinal uptake of [18F]EFB appears sig-
nificantly higher in LPS compared to that in untreated
rats, although individual time points did not reach
significance (Fig. 8). This suggests that the tracer has po-
tential to discern between high and low P2X7 expression
in vivo.
The difference in blood tracer quantification values
noticeable in Fig. 8 can be a result of partial volume ef-
fects arising from the inherently limited dimensions of
the blood ROI (the coronary artery lumen), whereas the
blood concentration of the tracer resulting from the
90 min biodistribution appears substantially unvaried in
the two groups. Furthermore, the 90 min biodistribution
data shows an increased, albeit non-significant, tracer
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Fig. 9 Biodistribution of [18F]EFB at 90 min post-injection in LPS (blue bars) vs. control (red bars) rats. The insert is a blow-up of some regions of
interest with low tracer accumulation
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uptake in the LPS rats’ upper digestive organs (stomach,
pancreas), possibly due to the relative abundance of
P2X7 receptors on the epithelial lining of the digestive
organs.
The preclinical evaluation was intended as a prelimin-
ary assessment of the BBB permeability and overall dis-
tribution of the tracer in LPS and control rats. While it
was not possible to perform metabolite and kinetic ana-
lysis at this stage, further work aiming to explore EFB
scaffold variants could benefit from such data. Moreover,
the injected activity was modest for some rats, and
[18F]EFB required extensive synthesis time. This process
may benefit from automation or a revised synthetic
protocol, such as one including a better precursor leav-
ing group for the final step of the radiosynthetic proced-
ure (step c, Fig. 2).
Conclusions
The work presented here constitutes an important step
towards the development of a fluorine-18-labelled PET
tracer useful for imaging P2X7 in vivo. The synthesis
and radiosynthesis of [18F]EFB have been successfully
carried out, affording the tracer in >99% RCP and
>300 GBq/μmol molar activity. In vitro calcium influx
binding assays revealed a Ki of 2.88 nM in human P2X7,
36.1 nM in rat and 547 nM in mouse.
A preliminary in vivo evaluation indicated a low BBB
uptake indicative of limited suitability of the molecule for
P2X7 brain PET imaging. Taken together with previous
work by Janssen [6] on a different radiotracer targeting
P2X7, this data is suggestive of limited compatibility of
the cyanoguanidine moiety with BBB entry in rats. Never-
theless, the altered mean longitudinal uptake in LPS ver-
sus control rats indicates that the tracer may have
potential as a systemic P2X7 PET imaging agent.
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